3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Interventions
Azacitidine
10
Cyclophosphamide
9
venetoclax
7
fludarabine phosphate
7
fludarabine
6
Whole-Body Irradiation
6
Biopsy
6
Tacrolimus
5
Mycophenolic Acid
5
Injections
5
Decitabine
5
Busulfan
5
decitabine and cedazuridine drug combination
4
Specimen Handling
4
Peripheral Blood Stem Cell Transplantation
4
Cytarabine
4
cedazuridine
3
Stem Cell Transplantation
3
Cyclosporine
3
X-Rays
2
Vorinostat
2
Sirolimus
2
Rituximab
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
Lenalidomide
2
Granulocyte Colony-Stimulating Factor
2
Filgrastim
2
Etoposide
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myelomonocytic, Chronic
×
bexmarilimab
×
90 days
×
Clear all
NCT05428969
2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2
Active not recruiting
181 enrolled